Based on the findings that higher SLC25A10 was associated with better prognosis in ovarian cancer patients, we assumed that elevated SLC25A10 expression may be beneficial to improve the overall survival time of patients. This evidence concerns the gene SLC25A10 and ovarian carcinoma.